Elicera Therapeutics AB operates as a clinical stage immuno-oncology company, which engages in the development of cell and gene therapies for immune-based cancer treatments. Its drug candidates are in the field of oncolytic viruses and in the field of cell therapies, in addition to a platform technology called iTANK (ImmunoTherapies Activated with Nap for efficient Killing) for further immune enhancement of treatments in said fields. Its product pipeline includes ELC-100, ELC-201, ELC-301, and ELC-401. The company was founded by Jamal El-Mosleh, Di Yu, and Magnus Essand in 2014 and is headquartered in Gothenburg, Sweden.